US Oncology Network Selects Provider for Cancer Testing
News Oct 05, 2016
Myriad Genetics, Inc. and The US Oncology Network announced that Myriad Genetic Laboratories has been selected as its preferred provider laboratory for hereditary cancer testing. The US Oncology Network is one of the nation's largest networks of integrated, community-based, and independent physician practices dedicated to advancing high-quality, evidence-based cancer care. With more than 1,000 affiliated physicians in 19 states, providers in The Network treat over 800,000 patients every year.
As part of the collaboration, Myriad and The US Oncology Network will work together to perform hereditary cancer research through the Genetic Risk Evaluation and Testing (GREAT) program within The Network affiliated practices. Under this program, the two organizations will collaborate to create a database that links patient outcomes with genetic test results. Principal among the research aims of this program is to better understand the genotype-phenotype correlation, gene prevalence, and research related to improving patient counselling and access to testing. The scale achieved by combining the largest hereditary cancer testing laboratory in the world with the more than 350 sites of care affiliated with The US Oncology Network will lead to unprecedented insights into the field of oncology.
"We are excited to work with Myriad as they have been a pioneer in personalized medicine for more than 25 years and have an unmatched reputation for diagnostic accuracy and customer service," said Michael Seiden, MD, PhD, chief medical officer of The US Oncology Network. "Additionally, Myriad's expertise and scientific leadership, having authored or co-authored over 50 peer-reviewed publications in the last three years, makes them an ideal research collaborator for The US Oncology Network."
"We are exceptionally pleased to work with The US Oncology Network, and are honored by their recognition of Myriad as a preferred provider laboratory," said Johnathan M. Lancaster, MD, PhD, chief medical officer of Myriad Genetic Laboratories, Inc. "We share with The Network an absolute commitment to the highest possible quality of clinical care. We will continue to invest in both research and customer service, which set Myriad apart as the industry gold-standard for hereditary cancer testing."
“Tracking” Nanoagents Can Illuminate Very Small Diseased TissuesNews
Polymer nanoagents that can ‘light up’ tiny areas of diseased tissues that conventional methods fail to detect, have been created by a research team led by Nanyang Technological University, Singapore.READ MORE
Training Evolution in Pathology Needed to Deliver Precision MedicineNews
The future delivery of precision medicine is at risk unless pathology training programmes evolve to embrace genomics, warn UK researchers.READ MORE